CN102869361A - 用于治疗耐抗有丝分裂剂的癌症的n-4(-((3-(2-氨基-4-嘧啶基)-2-吡啶基)氧基)苯基)-4-(4-甲基-2-噻吩基)-1-酞嗪胺 - Google Patents

用于治疗耐抗有丝分裂剂的癌症的n-4(-((3-(2-氨基-4-嘧啶基)-2-吡啶基)氧基)苯基)-4-(4-甲基-2-噻吩基)-1-酞嗪胺 Download PDF

Info

Publication number
CN102869361A
CN102869361A CN2010800512813A CN201080051281A CN102869361A CN 102869361 A CN102869361 A CN 102869361A CN 2010800512813 A CN2010800512813 A CN 2010800512813A CN 201080051281 A CN201080051281 A CN 201080051281A CN 102869361 A CN102869361 A CN 102869361A
Authority
CN
China
Prior art keywords
cancer
amg
cells
treatment
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800512813A
Other languages
English (en)
Chinese (zh)
Inventor
M.佩顿
R.肯达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102869361(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN102869361A publication Critical patent/CN102869361A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800512813A 2009-09-11 2010-09-09 用于治疗耐抗有丝分裂剂的癌症的n-4(-((3-(2-氨基-4-嘧啶基)-2-吡啶基)氧基)苯基)-4-(4-甲基-2-噻吩基)-1-酞嗪胺 Pending CN102869361A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24152709P 2009-09-11 2009-09-11
US61/241527 2009-09-11
PCT/US2010/048247 WO2011031842A1 (en) 2009-09-11 2010-09-09 N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer

Publications (1)

Publication Number Publication Date
CN102869361A true CN102869361A (zh) 2013-01-09

Family

ID=43216900

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800512813A Pending CN102869361A (zh) 2009-09-11 2010-09-09 用于治疗耐抗有丝分裂剂的癌症的n-4(-((3-(2-氨基-4-嘧啶基)-2-吡啶基)氧基)苯基)-4-(4-甲基-2-噻吩基)-1-酞嗪胺

Country Status (34)

Country Link
US (1) US20120028917A1 (https=)
EP (2) EP2475368B1 (https=)
JP (1) JP5851403B2 (https=)
KR (1) KR20120082896A (https=)
CN (1) CN102869361A (https=)
AU (1) AU2010292225C1 (https=)
BR (1) BR112012008325A2 (https=)
CA (1) CA2773838C (https=)
CL (1) CL2012000640A1 (https=)
CR (1) CR20120171A (https=)
DK (1) DK2475368T3 (https=)
EA (1) EA020526B1 (https=)
ES (1) ES2528485T3 (https=)
HK (1) HK1205457A1 (https=)
HR (1) HRP20150104T1 (https=)
HU (1) HUE024568T2 (https=)
IL (1) IL218569A0 (https=)
MA (1) MA33658B1 (https=)
ME (1) ME02048B (https=)
MX (1) MX2012003041A (https=)
NZ (1) NZ598758A (https=)
PE (1) PE20120895A1 (https=)
PH (1) PH12012500504A1 (https=)
PL (1) PL2475368T3 (https=)
PT (1) PT2475368E (https=)
RS (1) RS53807B1 (https=)
SG (1) SG179102A1 (https=)
SI (1) SI2475368T1 (https=)
SM (1) SMT201500028B (https=)
TN (1) TN2012000110A1 (https=)
TW (1) TW201121956A (https=)
UA (1) UA107675C2 (https=)
WO (1) WO2011031842A1 (https=)
ZA (1) ZA201202472B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109313197A (zh) * 2016-04-15 2019-02-05 费利克斯疗法公司 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合
CN114634483A (zh) * 2014-02-21 2022-06-17 弗洛斯特生物科技有限公司 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015518053A (ja) * 2012-05-31 2015-06-25 アムジエン・インコーポレーテツド 癌の治療のためのａｍｇ９００の使用
CN103664737A (zh) * 2012-09-25 2014-03-26 杨子娇 一类治疗房角狭窄的化合物及其用途
US9963701B2 (en) 2013-09-30 2018-05-08 Korea Institute Of Radiological & Medical Sciences Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor
HRP20220718T1 (hr) 2013-11-11 2022-09-30 Amgen Inc. Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka
US10053452B2 (en) 2013-12-03 2018-08-21 Amgen Inc. Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
MA50077A (fr) 2017-09-08 2020-07-15 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
WO2019213516A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES3060664T3 (en) 2018-06-12 2026-03-27 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101405282A (zh) * 2006-01-23 2009-04-08 安姆根有限公司 极光激酶调节剂和使用方法
CN101448501A (zh) * 2006-05-16 2009-06-03 阿斯利康(瑞典)有限公司 用于癌治疗的组合疗法
CN101448823A (zh) * 2006-05-16 2009-06-03 阿斯利康(瑞典)有限公司 Azd1152的马来酸酯（盐）共晶体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178318A1 (en) * 2003-07-03 2006-08-10 Shubha Anand Use of aurora kinase inhibitors for reducing the resistance of cancer cells
AU2007208351C1 (en) * 2006-01-23 2011-07-07 Amgen Inc. Aurora kinase modulators and method of use
US7560551B2 (en) * 2006-01-23 2009-07-14 Amgen Inc. Aurora kinase modulators and method of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101405282A (zh) * 2006-01-23 2009-04-08 安姆根有限公司 极光激酶调节剂和使用方法
CN101448501A (zh) * 2006-05-16 2009-06-03 阿斯利康(瑞典)有限公司 用于癌治疗的组合疗法
CN101448823A (zh) * 2006-05-16 2009-06-03 阿斯利康(瑞典)有限公司 Azd1152的马来酸酯（盐）共晶体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELIZABETH A HARRINGTON, ET AL.: "VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo", 《NATURE MEDICINE》 *
G. MOUNTZIOS, ET AL.: "Aurora kinases as targets for cancer therapy", 《CANCER TREATMENT REVIEWS》 *
SHUBHA ANAND, ET AL.: "AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol", 《CANCER CELL》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114634483A (zh) * 2014-02-21 2022-06-17 弗洛斯特生物科技有限公司 用于治疗癌症和增殖性疾病的抗有丝分裂酰胺
CN109313197A (zh) * 2016-04-15 2019-02-05 费利克斯疗法公司 使用静止细胞靶向和有丝分裂抑制剂的用于治疗肿瘤的组合

Also Published As

Publication number Publication date
AU2010292225C1 (en) 2013-06-27
EP2818170B1 (en) 2018-12-05
EP2818170A1 (en) 2014-12-31
JP2013504582A (ja) 2013-02-07
EA201270383A1 (ru) 2013-04-30
CA2773838A1 (en) 2011-03-17
IL218569A0 (en) 2012-05-31
RS53807B1 (sr) 2015-06-30
JP5851403B2 (ja) 2016-02-03
PE20120895A1 (es) 2012-08-19
CR20120171A (es) 2012-08-09
PL2475368T3 (pl) 2015-05-29
TN2012000110A1 (en) 2013-09-19
TW201121956A (en) 2011-07-01
NZ598758A (en) 2013-12-20
WO2011031842A1 (en) 2011-03-17
HRP20150104T1 (xx) 2015-03-13
US20120028917A1 (en) 2012-02-02
MA33658B1 (fr) 2012-10-01
MX2012003041A (es) 2012-06-27
CA2773838C (en) 2016-05-31
EP2475368A1 (en) 2012-07-18
SI2475368T1 (sl) 2015-03-31
EP2475368B1 (en) 2014-12-17
HK1173655A1 (en) 2013-05-24
EA020526B1 (ru) 2014-11-28
ZA201202472B (en) 2012-12-27
AU2010292225A1 (en) 2012-04-12
DK2475368T3 (en) 2015-03-09
PT2475368E (pt) 2015-02-10
ME02048B (me) 2015-05-20
KR20120082896A (ko) 2012-07-24
HK1205457A1 (en) 2015-12-18
HUE024568T2 (hu) 2016-02-29
ES2528485T3 (es) 2015-02-10
PH12012500504A1 (en) 2015-04-29
SG179102A1 (en) 2012-04-27
UA107675C2 (xx) 2015-02-10
CL2012000640A1 (es) 2012-09-21
BR112012008325A2 (pt) 2017-08-29
AU2010292225B2 (en) 2012-12-13
SMT201500028B (it) 2015-03-05

Similar Documents

Publication Publication Date Title
CN102869361A (zh) 用于治疗耐抗有丝分裂剂的癌症的n-4(-((3-(2-氨基-4-嘧啶基)-2-吡啶基)氧基)苯基)-4-(4-甲基-2-噻吩基)-1-酞嗪胺
EP3493848B1 (en) Heterocyclic diamidines
US20250339445A1 (en) Modulators of Orphan Nuclear Receptors for Treating Pancreatitis, Glioblastoma, Sarcopenia and Stroke
US9795595B2 (en) Methods for treating cancer
EP3787631B1 (en) Modulators of orphan nuclear receptors for nash and other metabolic disorders
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
HK1173655B (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
KR20240128955A (ko) 암 치료제로서의 강력하고 선택적인 smarca2 분해 키메라 분자

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20170620